Stocks
Seagen Inc.SGEN
NASDAQHealthcareBiotechnology$228.74-0.07%
Price as of · delayed, not real-time
A biotechnology firm specializing in cancer treatments, Seagen develops and commercializes targeted therapies for solid tumors and blood cancers. The company is a key player in antibody-drug conjugate (ADC) technology, attracting investor interest due to its pipeline of oncology drugs and partnerships with major pharmaceutical firms.
Market Cap: $43.2B52W Range: $126.47-$228.96
Congressional Interest in Seagen Inc. (SGEN)
6 members of Congress have disclosed 16 trades in Seagen Inc. (SGEN), a Healthcare company. The buy/sell breakdown shows 6 purchases versus 9 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
16
Unique Politicians
6
Buys
6
Sells
9
Who in Congress Is Trading SGEN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-10-27 | Josh Gottheimer | sell | $1K-$15K |
| 2023-06-26 | Josh Gottheimer | sell | $1K-$15K |
| 2023-05-19 | Josh Gottheimer | sell | $1K-$15K |
| 2023-03-06 | Daniel Goldman | buy | $1K-$15K |
| 2022-10-17 | Josh Gottheimer | buy | $1K-$15K |
| 2022-02-18 | Josh Gottheimer | sell | $1K-$15K |
| 2021-05-17 | Josh Gottheimer | sell | $1K-$15K |
| 2021-02-16 | Peter Meijer | sell | $796+ |
| 2020-08-03 | Josh Gottheimer | buy | $1K-$15K |
| 2020-04-30 | Josh Gottheimer | buy | $1K-$15K |
| 2020-02-18 | Josh Gottheimer | buy | $1K-$15K |
| 2019-06-24 | Donna Shalala | sell | $1K-$15K |
| 2018-01-19 | MICHAEL T. MCCAUL | sell | $1K-$15K |
| 2018-01-05 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2017-04-17 | MICHAEL T. MCCAUL | sell | $1K-$15K |
| 2015-06-18 | JAMES B. RENACCI | exchange | $1K-$15K |